6 completed, 2 recruiting. 8 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Completed 6, Recruiting 2 |
| Phase 1 | 2 | Completed 1, Recruiting 1 |
Follow ESRD: new trials by email Literature Review of ESRD trials Research Report on ESRD
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effect of Canagliflozin on Ultrafiltration & Fibrosis in Patients on Peritoneal Dialysis Canagliflozin 300 MG - ESRD, CKD (Chronic Kidney Disease) Stage 5D | Phase 2 | Recruiting | McGill University Health Centre/Research Institute of the McGill University Health Centre | 30 | 2026-02-01 | 2026-03-16 |
| Adding Urea to the Final Dialysis Fluid Urea in the dialysate - Dysequilibrium Syndrome, ESRD | Phase 1 / Phase 2 | Recruiting | University of California, San Francisco | 20 | 2025-09-16 | 2026-02-12 |
| The Effects of Patiromer on Serum Potassium Level and Gut Microbiome of ESRD Patients With Hyperkalemia Patiromer - ESRD, Hyperkalemia | Phase 2 | Completed | Dominic Raj | 27 | 2017-11-01 | 2023-05-09 |
| Effect of SNF472 on Progression of Cardiovascular Calcification in End-Stage-Renal-Disease (ESRD) Patients on Hemodialysis (HD) SNF472, Placebo - Cardiovascular Diseases, Cardiovascular Abnormalities | Phase 2 | Completed | Sanifit Therapeutics S. A. | 274 | 2016-11-01 | 2021-04-15 |
| Apixaban in End-stage Kidney Disease : A Pharmacokinetics Study apixaban - ESRD, Anticoagulant Toxicity | Phase 2 | Completed | Universitaire Ziekenhuizen KU Leuven | 24 | 2016-09-25 | 2018-10-17 |
| Nutrition, Inflammation and Insulin Resistance in End Stage Renal Disease-Aim 2 anakinra, actos, placebo - ESRD | Phase 2 | Completed | VA Office of Research and Development | 33 | 2014-10-22 | 2025-02-06 |
| Pharmacodynamic Study of AZD1722 in End-stage Renal Disease Patients on Hemodialysis AZD1722 (in-patient), Placebo (in-patient), AZD1722 (out-patient) - End Stage Renal Disease, Chronic Kidney Disease Stage 5 | Phase 2 | Completed | Ardelyx | 88 | 2013-01-01 | 2020-08-10 |
| Use of a Lifeline Graft in the A-V Shunt Model Lifeline - ESRD, Hemodialysis | Phase 1 / Phase 2 | Completed | Cytograft Tissue Engineering | 2004-09-01 | 2013-07-17 |
Kidney Failure, Chronic (8) · Hyperkalemia (2) · Renal Insufficiency, Chronic (2) · Acidosis (1) · Calcinosis (1) · Cardiovascular Abnormalities (1) · Cardiovascular Diseases (1) · Dysequilibrium syndrome (1) · Peritoneal Fibrosis (1) · Vascular Calcification (1)
Chronic Disease (8) · Disease Attributes (8) · Female Urogenital Diseases (8) · Female Urogenital Diseases and Pregnancy Complications (8) · Kidney Diseases (8) · Male Urogenital Diseases (8) · Pathologic Processes (8) · Pathological Conditions, Signs and Symptoms (8) · Renal Insufficiency (8) · Urogenital Diseases (8) · Urologic Diseases (8) · Renal Insufficiency, Chronic (6) · Metabolic Diseases (3) · Nutritional and Metabolic Diseases (3) · Water-Electrolyte Imbalance (2)
Blood Vessel Prosthesis (1) · Canagliflozin (1) · Interleukin 1 Receptor Antagonist Protein (1) · Pioglitazone (1) · SNF472 (1) · Urea (1) · apixaban (1) · patiromer (1) · tenapanor (1)
Ardelyx (1) · Cytograft Tissue Engineering (1) · Dominic Raj (1) · McGill University Health Centre/Research Institute of the McGill University Health Centre (1) · Sanifit Therapeutics S. A. (1) · Universitaire Ziekenhuizen KU Leuven (1) · University of California, San Francisco (1) · VA Office of Research and Development (1)
United States (5) · Argentina (1) · Belgium (1) · Canada (1) · Poland (1) · Spain (1) · United Kingdom (1)
Alex Gold, MD (1) · David P Rosenbaum, PhD (1) · Lech Cierpka, MD PhD (1) · Ramin Sam, MD (1) · Talat A Ikizler, MD (1) · Thomas A. Mavrakanas, MD, MSc. (1)
PMID 31707860, PMID 32750456, PMID 33835939, PMID 38178557, PMID 38384289
2015 (1), 2025 (1), R44HL064462 (1)